RT David Rennie (@DSORennie)Singapore is the model pupil of the world economy. It grew rich by studying hard, doing its homework and riding the wave of late 20C globalisation. Now it fears a global economy where FDI and trade flows follow politics and tariffs set by Trumpian caprice. https://t.co/uI9JshkNdX ...

Financial Data and Key Metrics Changes - Total revenue for the first half of 2025 reached RMB 3,731 million, representing a year-on-year increase of 74.3% [4] - Drug sales achieved RMB 641 million with a year-on-year growth of 53.5% [4][13] - Net loss for 2025 significantly narrowed to RMB 35.6 million, a decrease of 86.7% year-on-year [4][15] - Cash position stood at RMB 7,600 million, equivalent to approximately USD 1,100 million [15] Business Line Data and Key Metrics Changes - The company reported strong performance in its hematology oncology segment, particularly with the drug Orillah, which achieved over 50% growth in the first half of 2025 [18] - Tafasitamab was approved as the first CD19 antibody product for treating DLBCL patients in China, contributing to revenue growth [14][18] - The company is transitioning to a diversified multi-franchise portfolio, with several late-stage drivers expected to add durable revenue growth [14] Market Data and Key Metrics Changes - The market potential for ITP is estimated to be around RMB 1 billion to 1.5 billion in China, while the potential for SLE is around RMB 3 billion [60] - The company anticipates significant market opportunities in autoimmune diseases, with a focus on expanding its patient base [22][46] Company Strategy and Development Direction - The company aims to expand its international presence through strategic collaborations, such as the partnership with Prolyom for developing and commercializing ICP B02 [16] - The focus is on advancing its clinical pipeline, particularly in hematology and autoimmune diseases, with several drugs in late-stage trials [15][22] - The company is committed to maintaining a strong R&D backbone, with R&D expenses increasing to RMB 450 million, reflecting its commitment to innovation [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving at least 35% growth for Orillah in 2025, driven by strong market demand and unique product positioning [19] - The company is optimistic about the upcoming approvals and market entries for its drugs, which are expected to significantly enhance revenue streams [14][22] - Management highlighted the importance of patient enrollment in ongoing clinical trials to support future growth [9][10] Other Important Information - The company has made significant progress in its R&D pipeline, with multiple drugs in various stages of clinical trials, including BCL2 inhibitors and BTK inhibitors [5][10] - The company is actively pursuing global trials for its drugs, particularly in the areas of AML and MDS, to capitalize on unmet medical needs [36][41] Q&A Session Summary Question: Regarding Orillah's performance and future guidance - Management confirmed that Orillah achieved over 50% growth in the first half of 2025, exceeding the annual guidance of 35% [58] - The company is confident in its ability to raise guidance based on strong market performance and upcoming product approvals [59] Question: Expectations for pricing negotiations and R&D expenses - Management is preparing for negotiations related to pricing and expects to provide unique value to patients, which will support sales momentum [65] - R&D expenses are projected to increase as the company invests in late-stage clinical trials and global initiatives [69] Question: Global trials for BCL2 inhibitors - Management indicated that while there are excellent results for first-line CLL, the focus will initially be on launching in China before considering global trials [73] Question: Progress on lupus indication and ADC pipeline - Management expects to have top-line results for the lupus indication by September and is optimistic about the ADC pipeline's potential [88][90]

Globalization can survive the US trade war; the prosperity gains are too great for the rest of the world to abandon it, writes @chrismbryant (via @opinion) https://t.co/PG0qvJ3KYs ...

All right, those results that you just put out there, what exactly stood out to you as you as you looked as a chief executive on the quarter that was, what exactly was the main driver for those results that you had in this past quarter. Yeah, our exceptional results are really the result of the resilience of the 2 million customers we serve around the globe. in 190 countries and territories exporting their goods and services.We saw, as you said, 16% revenue growth, 37% revenue growth in our B2B segment, 25% ...

Economic Uncertainty & Recession Risks - Uncertainty, stemming from policy, geopolitical factors, and President Trump's attacks on the Federal Reserve, poses a significant threat to US economic growth [1][2] - Recession risks are higher than average, though not overwhelming, as the US consumer remains resilient [7][9] - Corporate investment is hindered by uncertainty, impacting medium to longer-term plans [5] Monetary Policy & Inflation - It's difficult to argue for lower interest rates currently due to uncertainty about future inflation [11] - There are no overwhelming signs of weakening economic activity that would call for monetary policy stimulus [12] - The pass-through of tariffs into higher prices has been modest so far, but it's still early stages [11] Immigration & Demographics - Slower population growth due to immigration shocks negatively impacts medium-term potential output [8][9] - Aging populations and declining birth rates in the US and other advanced economies impact potential growth [14] - Immigration has historically contributed to trend growth in the US economy [8][14] Debt & Fiscal Policy - The US budget bill is estimated to add at least $3 trillion to the deficit over the next 9 to 10 years [15] - High debt levels and debt servicing costs are a concern, potentially hindering more productive investments [17][18] Globalization & Trade - Globalization has been off its peak since the global financial crisis [20] - While globalization has benefited consumers through cheaper products, it has also led to a hollowing out of various sectors in the US [20][22] - Increased global cooperation is preferred over a fragmented system [22] Global Debt Crisis - The unfolding debt crisis in low-income countries is something to watch, as it could amplify to emerging markets with bigger footprints [24][25]

Financial Data and Key Metrics Changes - Cboe reported a 14% year-over-year increase in net revenue, reaching a record $587 million, and adjusted diluted EPS also rose by 14% to $2.46 [6][20] - Adjusted operating expenses increased by 8% year-over-year to $213 million, while adjusted operating EBITDA grew by 19% to $387 million, resulting in an adjusted operating EBITDA margin expansion of 2.3 percentage points to 65.8% [20][24] Business Line Data and Key Metrics Changes - Derivatives markets net revenues grew by 17%, with options volumes increasing significantly due to heightened market volatility [7][20] - The Options segment achieved a record net revenue growth of 19% year-over-year, with a 20% increase in total Options average daily volume [21] - DataVantage business net revenue improved by 11% year-over-year, driven by strong new subscription and unit sales [14][23] Market Data and Key Metrics Changes - The European cash equities business drove an 11% increase in cash and spot markets net revenue, with Europe and Asia Pacific segments achieving a 30% year-over-year growth [12][22] - Net transaction and clearing fees in the Europe and APAC segment rose by 39% year-over-year, reflecting strong industry volumes [12][22] Company Strategy and Development Direction - The company is focused on optimizing growth in core businesses while exploring organic and inorganic investment opportunities [31][32] - Cboe's decision to close its Japan equities business reflects a strategy to redirect resources to higher potential return activities [13][26] - The management emphasizes the importance of capital allocation and is committed to assessing the business portfolio for long-term shareholder returns [32][78] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential of options as an asset class, driven by continued uncertainty in monetary and trade policy [11][31] - The company remains committed to enhancing its product offerings and expanding its global presence, particularly in the Asia Pacific region [15][66] Other Important Information - Cboe expects to record a pretax charge of approximately $5 million related to the wind down of its Japanese equities business, which will be excluded from adjusted operating expenses [26] - The company repurchased $35 million in shares during the quarter, with year-to-date repurchases totaling $65 million [28] Q&A Session Summary Question: Key priorities for the new CEO - The new CEO emphasized optimizing growth in core businesses and exploring compelling inorganic growth opportunities, while maintaining a flexible balance sheet [38][39] Question: Evaluation of business footprint - The CEO indicated that the company is rigorously evaluating all business operations to ensure capital is allocated to the best growth opportunities [42] Question: DataVantage revenue guidance - Management remains confident in the full-year guidance for DataVantage, noting strong momentum in new subscription sales and international demand [46][49] Question: Long-term growth for index options volume - The management highlighted the sustainability of zero DTE volumes and the potential for growth through retail broker partnerships and international expansion [51][53] Question: Competitive environment for single stock zero DTE - Management sees single stock zero DTEs as complementary to index options, with retail traders likely to migrate to index options as their sophistication increases [55][56] Question: Relationship with S&P Global - The CEO reaffirmed the long-term partnership with S&P Global and the importance of mutual growth and innovation [60][63] Question: Globalization strategy - The company is focused on importing flow from outside the U.S. into its markets, leveraging data as a key driver for growth [66] Question: Industry evolution and retail engagement - Management views the growth in retail engagement as a long-term trend and is committed to remaining relevant in a dynamic environment [71][73]

Trade Agreement Negotiation - The industry views current framework deals as the start of negotiating rounds that may span weeks, months, or even years [1] - Addressing politically entrenched trade issues between countries takes a long time [2] - The use of tariffs is a tactic to bring parties to the negotiating table [3] Trade Policy & Tariffs - The administration aims to rebalance trade and bring back manufacturing jobs [5] - Tariffs are seen as leverage to get countries to the negotiating table [6] - The average tariff rate is nearly 20% [8] Globalization Impact - The US has benefited from globalization, but concerns exist regarding its impact, particularly after China's admission to the WTO [7] - The administration is responding to the perceived negative impacts of globalization [7] Market & Economic Outlook - The stock market is performing well despite high tariff levels [8] - Consumer prices have increased, but not to a concerning degree [8] - Inflation has ticked up, but has not yet become a significant headwind [9]

Group 1 - The core viewpoint of the forum emphasizes that the sustainable innovation path for Chinese innovative pharmaceutical companies lies not only in "going out" and "bringing in," but also in finding breakthroughs in sustainability [2] - Chinese innovative pharmaceutical companies face significant challenges in international expansion, including regulatory communication, indication selection, and clinical verification, which test their resource allocation and long-term strategic capabilities [2] - Multinational pharmaceutical companies are accelerating localization in the Chinese market, requiring more flexible strategic implementation and deep local cooperation to respond to the rapid development of domestic innovation [2] Group 2 - Organizational structure, talent systems, and management language discrepancies often lead to internal friction for Chinese pharmaceutical companies during their internationalization process [3] - AI technology is rapidly penetrating pharmaceutical companies' commercialization, research and development, and compliance processes, reshaping management boundaries [3] - The relationship between localization and globalization is highlighted as essential for stability and enhancing strategic positioning, with sustainability being a prerequisite for long-term value [3]

Societal Transformation - Romania experienced a shift from a 99.9% homogeneous population due to foreign investments and EU grants [1] - Increased foreign investment correlates with the emergence of societal problems [2] - Europe is undergoing significant changes, anticipating a completely different world in 50 years [1] Economic Impact - Foreign investments have led to the presence of wealthy individuals and diverse occupations [1] Potential Challenges - Increased prosperity may be accompanied by negative societal elements [1][2] - Maintaining international competitiveness without exacerbating societal issues presents a challenge [1]

Group 1 - TCL has completed its campus recruitment for 2025, hiring over 2500 fresh graduates, a year-on-year increase of 26.8% [1] - The new hires, referred to as "Chicks," are primarily focused on two areas: technology research and globalization [1][2] - In the technology research area, the majority of the new hires are concentrated in fields such as materials science, electronic information engineering, optoelectronics, and mechanical design, with 68.8% of positions supporting semiconductor display, new energy photovoltaic, and intelligent manufacturing [1][2] Group 2 - The globalization direction includes roles in overseas marketing, localized supply chain, international legal affairs, and finance, with a 24.6% year-on-year increase in hiring from overseas institutions [2] - TCL's founder, Li Dongsheng, emphasized the company's strategy to establish five regional operational centers globally to support its globalization efforts [2][4] - TCL has been implementing a "troop storage campus" strategy for 28 years, viewing campus recruitment as a core investment for future competitiveness, with over 12,000 positions for fresh graduates planned from 2022 to 2025 [4] Group 3 - The "Chick" talent development system includes a structured training program called the "Chick Plan," designed to help new hires transition effectively into the workplace [5] - Key projects such as the TCL Huaxing Guangzhou T9 production line and the TCL Zhonghuan Yinchuan 50GW photovoltaic monocrystalline smart factory rely on the participation of these new hires in critical technology development [5]